Susquehanna International Group, LLP Cerevel Therapeutics Holdings, Inc. Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	SELL	$38.96 - $42.75 $185,449 - $203,490	-4,760 Reduced 4.19%	108,832 $4.45 Million
Q1 2024 May 07, 2024	SELL	$40.88 - $43.27 $1.3 Million - $1.38 Million	-31,823 Reduced 21.88%	113,592 $4.8 Million
Q4 2023 Feb 14, 2024	BUY	$20.27 - $42.44 $2.41 Million - $5.04 Million	118,696 Added 444.24%	145,415 $6.17 Million
Q3 2023 Nov 14, 2023	SELL	$20.26 - $31.91 $140,482 - $221,263	-6,934 Reduced 20.6%	26,719 $583,000
Q2 2023 Aug 11, 2023	SELL	$23.9 - $35.38 $1.57 Million - $2.32 Million	-65,627 Reduced 66.1%	33,653 $1.07 Million
Q1 2023 May 16, 2023	BUY	$22.82 - $35.32 $1.75 Million - $2.7 Million	76,500 Added 335.82%	99,280 $2.42 Million
Q4 2022 Feb 14, 2023	SELL	$25.35 - $31.96 $888,340 - $1.12 Million	-35,043 Reduced 60.6%	22,780 $718,000
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $1.28 Million - $2.08 Million	50,194 Added 657.94%	57,823 $1.63 Million
Q2 2022 Aug 15, 2022	SELL	$20.62 - $37.15 $543,130 - $978,531	-26,340 Reduced 77.54%	7,629 $202,000
Q1 2022 May 16, 2022	SELL	$23.5 - $35.38 $1.1 Million - $1.65 Million	-46,694 Reduced 57.89%	33,969 $1.19 Million
Q4 2021 Feb 14, 2022	BUY	$29.21 - $44.64 $1.05 Million - $1.61 Million	36,009 Added 80.64%	80,663 $2.62 Million
Q3 2021 Nov 15, 2021	BUY	$21.26 - $38.85 $639,755 - $1.17 Million	30,092 Added 206.65%	44,654 $1.32 Million
Q2 2021 Aug 11, 2021	SELL	$12.56 - $29.69 $2.18 Million - $5.16 Million	-173,726 Reduced 92.27%	14,562 $373,000
Q1 2021 May 17, 2021	BUY	$12.37 - $17.74 $2.05 Million - $2.94 Million	165,788 Added 736.84%	188,288 $2.59 Million
Q4 2020 Feb 16, 2021	BUY	$9.82 - $18.27 $220,950 - $411,075	22,500 New	22,500 $373,000

Others Institutions Holding CERE

# of Institutions

Shares Held

5.01M

Call Options Held

3.3K

Put Options Held

View Full List

About Cerevel Therapeutics Holdings, Inc.

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

More about CERE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account